Loading...
Market
Will Relay Therapeutics receive the first commercial milestone payment from Elevar by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Relay Therapeutics' financial reports and press releases
Story
Relay and Elevar Sign Licensing Deal for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma, Potentially Worth $500 Million
Dec 3, 2024, 01:04 PM
Relay Therapeutics and Elevar Therapeutics have entered into an exclusive global licensing agreement for Lirafugratinib, a treatment aimed at FGFR2-driven cholangiocarcinoma and other solid tumors. Under the terms of the agreement, Relay Therapeutics is set to receive up to $500 million in total, which includes $75 million in upfront and regulatory milestone payments, as well as up to $425 million in potential commercial milestone payments and tiered royalties in the low-teens percentage range. This collaboration is expected to enhance Relay's oncology pipeline, particularly in addressing challenging cancer types.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Top 10 • 25%
Top 20 • 25%
Top 30 • 25%
Below Top 30 • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
